16 related articles for article (PubMed ID: 38637143)
1. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.
Gafita A; Rauscher I; Weber M; Hadaschik B; Wang H; Armstrong WR; Tauber R; Grogan TR; Czernin J; Rettig MB; Herrmann K; Calais J; Weber WA; Benz MR; Fendler WP; Eiber M
J Nucl Med; 2022 Nov; 63(11):1651-1658. PubMed ID: 35422442
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Performance of RECIP 1.0 Based on [
Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA
J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363
[TBL] [Abstract][Full Text] [Related]
3. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
Gafita A; Rauscher I; Fendler WP; Murthy V; Hui W; Armstrong WR; Herrmann K; Weber WA; Calais J; Eiber M; Weber M; Benz MR
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4271-4281. PubMed ID: 35767071
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with
Murthy V; Gafita A; Thin P; Nguyen K; Grogan T; Shen J; Drakaki A; Rettig M; Czernin J; Calais J
J Nucl Med; 2023 Nov; 64(11):1737-1743. PubMed ID: 37678927
[TBL] [Abstract][Full Text] [Related]
5. Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer.
Gafita A; Djaileb L; Rauscher I; Fendler WP; Hadaschik B; Rowe SP; Herrmann K; Calais J; Rettig M; Eiber M; Weber M; Benz MR; Farolfi A
Radiology; 2023 Jul; 308(1):e222148. PubMed ID: 37432081
[TBL] [Abstract][Full Text] [Related]
6. RECIP 1.0 Predicts Progression-Free Survival After [
Gafita A; Djaileb L; Rauscher I; Fendler WP; Hadaschik B; Rowe SP; Herrmann K; Solnes LB; Calais J; Rettig MB; Weber M; Farolfi A; Benz MR; Eiber M
J Nucl Med; 2024 Apr; ():. PubMed ID: 38637143
[TBL] [Abstract][Full Text] [Related]
7. Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Han S; Woo S; Kim YI; Lee JL; Wibmer AG; Schoder H; Ryu JS; Vargas HA
Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33917006
[TBL] [Abstract][Full Text] [Related]
8.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]